Alnylam Pharmaceuticals Competitive Intelligence & Landscape

Alnylam Pharmaceuticals (alnylam.com) is a leading independent biopharmaceutical company and a pioneer in RNA interference (RNAi) therapeutics. Founded in 2002 by distinguished researchers and biotech leaders, Alnylam has dedicated over two decades to making critical breakthroughs in the field of RNAi therapeutics. Their mission is to "silence disease" and "amplify life" by developing medicines that effectively silence the genes responsible for causing or contributing to various diseases [https://www.alnylam.com/, https://www.alnylam.com/about-alnylam].

The company's core work revolves around the science of RNAi, which offers a revolutionary approach to treating diseases.

Alnylam focuses on developing therapeutic areas and has a robust pipeline of clinical trials, showcasing their commitment to advancing this innovative science. Their efforts are supported by a strong leadership team and scientific advisory board [https://www.alnylam.com/about-alnylam, https://www.alnylam.com/].

Alnylam’s corporate headquarters and research laboratories are situated in Cambridge, MA, and the company was incorporated in Delaware in June 2002 [https://investors.alnylam.com/faq, https://investors.alnylam.com/sites/default/files/pdfs/2023-alnylam-10k.pdf]. They serve a target market of patients suffering from conditions such as amyloidosis, acute hepatic porphyria, and primary hyperoxaluria, offering patient services including genetic testing and counseling [https://www.alnylam.com/].

Alnylam has been publicly trading on the NASDAQ Stock Market under the symbol ALNY since May 2004 [https://investors.alnylam.com/faq, https://investors.alnylam.com/alny-stock-information].

Alnylam is committed to corporate responsibility and transparency, publishing annual reports and maintaining high standards of corporate governance for its employees, officers, and directors [https://investors.alnylam.com/, https://investors.alnylam.com/corporate-governance]. They also provide extensive resources for medical professionals, including support for investigator-initiated studies and early access programs [https://www.alnylam.com/].

Alnylam Pharmaceuticals focuses on RNAi therapeutics with a patient-centric approach to product access and affordability. Their product line includes approved therapies such as AMVUTTRA® (vutrisiran), ONPATTRO® (patisiran), GIVLAARI® (givosiran), and OXLUMO® (lumasiran) [https://www.alnylam.com/our-products]. Each of these products is supported by a personalized support program for patients.

Alnylam is committed to ensuring broad patient access, asserting that most patients prescribed their therapies pay $0 out of pocket [https://www.alnylam.com/sites/default/files/pdfs/alnylam-patient-access-philosophy-factsheet-03-25.pdf]. This is achieved through various initiatives, including the Alnylam Assist™ program, which helps U.S. patients with commercial copay programs and aims for zero cost-share for ONPATTRO®, GIVLAARI®, OXLUMO®, and AMVUTTRA® [https://www.alnylam.com/sites/default/files/2023-09/alny-papr-factsheet-alnypapre.pdf]. For example, 69% of U.S. patients for ONPATTRO® and AMVUTTRA® have zero cost-share, while for GIVLAARI®, this figure is 85% [https://www.alnylam.com/sites/default/files/2023-09/alny-papr-factsheet-alnypapre.pdf].

To further support access, Alnylam has implemented a Patient Access Philosophy that emphasizes proactive patient access and value-based agreements with payers. This philosophy includes a commitment not to increase the annualized price of their medicines above the consumer price index (CPI-U) unless significant new innovation has been achieved [https://investors.alnylam.com/press-release?id=22951]. They also offer Alnylam Act®, a no-charge, third-party genetic testing and counseling program for patients with suspected hereditary ATTR amyloidosis, acute hepatic porphyria, or primary hyperoxaluria type 1 [https://www.alnylam.com/medical-professional-resources/genetic-testing-counseling].

In addition to commercial products, Alnylam has an Early Access Program to help patients gain access to investigational medicines through compassionate use [https://www.alnylam.com/medical-professional-resources/early-access-program]. They also engage with medical professionals to provide information about their research, treatments in development, and access to investigational medicines [https://www.alnylam.com/medical-professional-resources]. The company's pipeline includes investigational RNAi therapeutics** for TTR Amyloidosis, cardiovascular, metabolic, neuroscience, hematology, and rare diseases [https://www.alnylam.com/alnylam-rnai-pipeline].

Alnylam Pharmaceuticals (alnylam.com) actively seeks to expand its workforce, with a strong focus on roles critical to its research, development, and commercialization of RNAi therapeutics. The company's careers page emphasizes an inclusive recruitment process and a commitment to equal employment opportunity, highlighting its dedication to fostering an environment where employees can thrive [alnylam.com/careers]. They also provide detailed information on applicant policies, including those for recruitment and staffing agencies, and warnings against fraudulent recruitment activity [alnylam.com/careers].

Hiring trends at Alnylam Pharmaceuticals indicate a strategic expansion in key scientific and leadership roles. Recent job postings include an "Executive Director, Pharmacometrics" with a posting date of February 8, 2026, and a "Director, Clinical Research-Neurology/Neuromuscular" posted on February 19, 2026, both located in Cambridge, MA [opportunities.alnylam.com/job/Cambridge-Executive-Director%2C-Pharmacometrics-MA-02142/1326768100/][opportunities.alnylam.com/job/Cambridge-Director%2C-Clinical-Research-MA-02142/1313051400/]. Other notable openings include an "Associate Director, Epidemiology" (April 19, 2026) and a "Scientist, Antibody Engineering" (March 21, 2026), further underscoring the company's investment in scientific expertise [opportunities.alnylam.com/job/Cambridge-Associate-Director%2C-Epidemiology-MA-02142/1366550500/][opportunities.alnylam.com/job/Cambridge-Scientist%2C-Antibody-Engineering-MA-02142/1366547100/].

These hiring patterns signal Alnylam Pharmaceuticals' sustained commitment to advancing its RNAi therapeutics pipeline and expanding its clinical and scientific capabilities. The emphasis on roles such as Pharmacometrics, Clinical Research, Epidemiology, and Antibody Engineering directly supports their core mission to "Silence disease. Amplify life™" through innovative drug development [alnylam.com]. While one position, "Director, Web Platform Engineering," was noted as filled, there is no public information about company-wide layoffs, suggesting a period of growth and specialized talent acquisition [opportunities.alnylam.com/job/Cambridge-Director%2C-Web-Technology-Lead-MA-02142/1359576300/].

Alnylam also actively recruits for its Commercial & Sales teams, highlighting the importance of connecting its development efforts with healthcare professionals, payers, patients, and caregivers. This indicates a robust commercialization strategy alongside its R&D focus [alnylam.com/commercial-sales]. The company emphasizes career development and supportive programs for its team members at various stages of their careers, aligning with its values of commitment to people and an open culture [alnylam.com/careers/working-at-alnylam].

Alnylam Pharmaceuticals (alnylam.com), a leading RNAi therapeutics company, has demonstrated robust financial performance with consistent revenue growth. In the first quarter of 2026, the company achieved global net product revenues of $1,036 million, marking a 121% increase compared to Q1 2025. This growth was primarily fueled by total TTR revenues, which reached $910 million, a 153% increase year-over-year [investors.alnylam.com/press-release?id=29796, investors.alnylam.com/sites/default/files/pdfs/alnylam-q1-2026-earnings-presentation.pdf]. For the full year 2025, Alnylam reported global net product revenues of $2,987 million, an 81% growth from 2024, with fourth-quarter revenues reaching $995 million [investors.alnylam.com/press-release?id=29551]. The company has also provided strong financial guidance for 2026, projecting combined net product revenues between $4,900 million and $5,300 million, with total TTR net product revenues expected to be between $4,400 million and $4,700 million [investors.alnylam.com/press-release?id=29796]. This follows a preliminary net product revenue of $1,646 million for 2024 for its key products ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO®, representing a 33% annual growth [investors.alnylam.com/press-release?id=28611].

Alnylam Pharmaceuticals consistently provides detailed financial information, including annual reports and SEC filings, accessible to investors on its dedicated investor relations portal [investors.alnylam.com/financial-information]. This transparency allows stakeholders to review the company's financial health and performance in depth. The company's financial statements show net sales of $3,713.937 million for the year ending December 2025, and $2,248.24 million for the year ending December 2024 [investors.alnylam.com/financial-statements].

Looking back at 2025, Alnylam had revised its guidance upwards, expecting total net product revenues to reach $2,950 million to $3,050 million, a $275 million or 10% increase at the midpoint from previous estimates [investors.alnylam.com/press-release?id=29381]. The first quarter of 2025 saw global net product revenues of $469 million, demonstrating 28% year-over-year growth, largely driven by a 36% increase from its hATTR-PN franchise [investors.alnylam.com/press-release?id=28956]. The company also publishes an annual Corporate Responsibility Report, detailing its progress against corporate responsibility goals [investors.alnylam.com/]. While specific fundraising rounds, valuations, and M&A activities were not detailed in the provided sources, the consistent reporting of increasing product revenues and optimistic future guidance indicates a strong financial footing for the company.

Alnylam Pharmaceuticals actively participates in and hosts a variety of events, primarily focusing on investor conferences and scientific webcasts to share company updates and research. The company's "Events & Presentations" section on its investor relations website is a key resource for information on both upcoming and past events, including access to webcasts [investors.alnylam.com/].

Alnylam frequently presents at significant investor conferences such as the BofA Securities Healthcare Conference, the TD Cowen 46th Annual Healthcare Conference, the UBS Global Healthcare Conference, and Citi's 2025 Biopharma Back to School Conference [investors.alnylam.com/press-release?id=29831][investors.alnylam.com/press-release?id=29601][investors.alnylam.com/press-release?id=29396][investors.alnylam.com/press-release?id=29236]. They also maintain a consistent presence at major events like the J.P. Morgan Healthcare Conference, where management provides company overviews and engages in Q&A sessions [investors.alnylam.com/press-release?id=29471].

In addition to external conferences, Alnylam hosts its own targeted webinars and events. Notable examples include the "Alnylam TTR Investor Webinar," which in 2026 highlighted progress in delivering for ATTR-CM patients and the long-term growth of the company's TTR franchise [investors.alnylam.com/press-release?id=29726][capella.alnylam.com/2026/03/24/ttr-webinar-2026]. They also conduct earnings conference calls, such as the Q1 2026 Earnings Conference Call [investors.alnylam.com/events], and host webcasts like the "RNAi Roundtable" series [investors.alnylam.com/press-releases]. These events are crucial for communicating with investors and the scientific community.